Close Menu
  • News
  • Stocks
  • Bonds
  • Commodities
  • Collectables
    • Art
    • Classic Cars
    • Whiskey
    • Wine
  • Trading
  • Alternative Investment
  • Markets
  • More
    • Economy
    • Money
    • Business
    • Personal Finance
    • Investing
    • Financial Planning
    • ETFs
    • Equities
    • Funds

Subscribe to Updates

Get the latest markets and assets news and updates directly to your inbox.

Trending Now

Comment | Galleries are looking to merch to keep spirits up—it’s a joyful move in challenging times – The Art Newspaper

October 17, 2025

Michelangelo Pistoletto: ‘AI will not destroy humanity, we are doing it ourselves’ – The Art Newspaper

October 17, 2025

‘We are in a very special situation as collectors’: Petr Pudil on opening the Kunsthalle Praha in Prague, and the art he collects – The Art Newspaper

October 17, 2025
Facebook X (Twitter) Instagram
Facebook X (Twitter) Instagram
The Asset ObserverThe Asset Observer
Newsletter
LIVE MARKET DATA
  • News
  • Stocks
  • Bonds
  • Commodities
  • Collectables
    • Art
    • Classic Cars
    • Whiskey
    • Wine
  • Trading
  • Alternative Investment
  • Markets
  • More
    • Economy
    • Money
    • Business
    • Personal Finance
    • Investing
    • Financial Planning
    • ETFs
    • Equities
    • Funds
The Asset ObserverThe Asset Observer
Home»Stocks
Stocks

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action “ BNTX

News RoomBy News RoomFebruary 12, 2024
Share
Facebook Twitter LinkedIn Pinterest Email


NEW YORK, Feb. 11, 2024 (GLOBE NEWSWIRE) —

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of BioNTech SE (NASDAQ: NASDAQ:) between March 30, 2022 and October 13, 2023, both dates inclusive (the Class Period), of the important March 12, 2024 lead plaintiff deadline.

SO WHAT: If you purchased BioNTech securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the BioNTech class action, go to https://rosenlegal.com/submit-form/?case_id=21850 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 12, 2024. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, defendants made materially false and misleading statements regarding BioNTech’s business, operations, and prospects. Specifically, defendants made false and/or misleading statements and/or failed to disclose that: (1) BioNTech overstated demand for Comirnaty, a COVID-19 vaccine, and/or its commercial prospects; (2) BioNTech and/or Pfizer Inc. (NYSE:) had accumulated excess inventory of raw materials for Comirnaty, as well as COVID-19 vaccine doses adapted to other, non-XBB.1.5 variants that were produced at risk; (3) accordingly, BioNTech was at an increased risk of recording significant inventory write-offs and other charges related to Comirnaty; and (4) as a result, defendants’ public statements were materially false and/or misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the BioNTech class action, go to https://rosenlegal.com/submit-form/?case_id=21850 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook (NASDAQ:): https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

               Laurence Rosen, Esq.
               Phillip Kim, Esq.
               The Rosen Law Firm, P.A.
               275 Madison Avenue, 40th Floor
               New York, NY 10016
               Tel: (212) 686-1060
               Toll Free: (866) 767-3653
               Fax: (212) 202-3827
               [email protected]
               [email protected]
               [email protected]
               www.rosenlegal.com



Read the full article here

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email

Keep Reading

Banks’ credit ‘cockroaches’ are spooking the stock market. Here’s what investors need to know.

Why record cash in money-market funds won’t necessarily flood into stocks, bonds

Trump rolls out his latest deal with a drugmaker. This one stems from his campaign promise to cover all IVF costs.

Lithium Americas is deemed vital by Trump, but investors beware, J.P. Morgan says

Jerome Powell may have just given stock investors a new reason to be worried

Praxis Precision’s tremor-drug trial succeeds where others have failed. The stock is skyrocketing.

Opinion: ‘Sell’ signs are showing up in the stock market — but this number matters most

Hedge funds’ use of controversial leveraged trade is missing from Treasury data, Fed paper finds

Zions takes $50 million loan loss as another credit ‘cockroach’ appears. Its stock is falling.

Recent Posts
  • Comment | Galleries are looking to merch to keep spirits up—it’s a joyful move in challenging times – The Art Newspaper
  • Michelangelo Pistoletto: ‘AI will not destroy humanity, we are doing it ourselves’ – The Art Newspaper
  • ‘We are in a very special situation as collectors’: Petr Pudil on opening the Kunsthalle Praha in Prague, and the art he collects – The Art Newspaper
  • Tequila from ‘premier cru’ wine barrel sells for $9k at Sotheby’s
  • In pictures: demand is high at the Pavilion of Art and Design – The Art Newspaper

Subscribe to Newsletter

Get the latest markets and assets news and updates directly to your inbox.

Editors Picks

Michelangelo Pistoletto: ‘AI will not destroy humanity, we are doing it ourselves’ – The Art Newspaper

October 17, 2025

‘We are in a very special situation as collectors’: Petr Pudil on opening the Kunsthalle Praha in Prague, and the art he collects – The Art Newspaper

October 17, 2025

Tequila from ‘premier cru’ wine barrel sells for $9k at Sotheby’s

October 17, 2025

In pictures: demand is high at the Pavilion of Art and Design – The Art Newspaper

October 17, 2025

Archaeologists from Costa Rica and Mexico restore ancient stone spheres at Unesco World Heritage site – The Art Newspaper

October 17, 2025
Facebook X (Twitter) Instagram
© 2025 The Asset Observer. All Rights Reserved.
  • Privacy Policy
  • Terms
  • Press Release
  • Advertise
  • Contact

Type above and press Enter to search. Press Esc to cancel.